Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Saved in:
| Title: | Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide. |
|---|---|
| Authors: | Nauck MA; Division of Diabetology, Medical Department I, St. Josef-Hospital (Ruhr-Universität Bochum), Bochum, Germany., Frossard JL; Division of Gastroenterology, University Hospital of Geneva, Geneva, Switzerland., Barkin JS; Division of Gastroenterology, Department of Medicine, University of Miami Leonard M. Miller School of Medicine, Miami, FL., Anglin G; Eli Lilly Canada, Toronto, Ontario, Canada., Hensley IE; Eli Lilly and Company, Indianapolis, IN., Harper KD; Eli Lilly and Company, Indianapolis, IN., Milicevic Z; Eli Lilly and Company, Vienna, Austria milicevic_zvonko@lilly.com. |
| Source: | Diabetes care [Diabetes Care] 2017 May; Vol. 40 (5), pp. 647-654. Date of Electronic Publication: 2017 Mar 10. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Diabetes Association Country of Publication: United States NLM ID: 7805975 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1935-5548 (Electronic) Linking ISSN: 01495992 NLM ISO Abbreviation: Diabetes Care Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1935-5548 |
|---|---|
| DOI: | 10.2337/dc16-0984 |
